Appropriately, this approach to personalized pathway analysis is strongly influenced by somatic alterations of common cancer driver genes, i.e., the somatic alteration of a gene like p53 will impact the predicted aberrant activity of many pathways whose expression-based activity is closely associated with somatic alterations in the tumor. The gene discussed is TP53; the disease is cancer.